ClinicalTrials.gg
CompletedNCT03041792Updated Jul 26, 2019Results posted

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

A Phase 1 interventional study of Liraglutide and Placebo in Obesity, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-26.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
41st of 79
61 · median 70
Started
2017
with 11 others
Phase 1
9 of 79
1 open now
Registered
39th of 79
by date

Among the 79 studies testing liraglutide in Obesity, this one is the 41st largest by enrollment, is one of 12 that started in 2017, is one of 9 in phase 1, and was the 39th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and female subjects;
  • 30-40 kg/m2;

Exclusion criteria

Exclusion Criteria:

  • Evidence of history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Active

    Liraglutide

    Drug: Liraglutide

  • Placebo comparator
    Placebo

    Placebo comparator

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5

    The mean energy intake was collected to assess the effect of liraglutide on food intake in non-diabetic, obese participants. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Mean energy intakes at Visit 4 was defined as the mean values of the measurements at Study Day 20 and 21. Same definition applies to Visit 5 (Study Day 41 and 42). Baseline was defined as the mean of Visit 3 (Study Day -1 and 0).

    Time frame: Visit 3, Visit 4 and Visit 5

Secondary outcomes

  1. Number of Participants With Vital Signs Data Meeting Categorical Criteria

    Absolute values and changes from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR) were recorded in supine position. Vital signs categorical summarization criteria were 1), blood pressure: SBP greater than or equal to (\>=) 30 millimeters of mercury (mm Hg) change from baseline, SBP less than (\<) 90 mm Hg; DBP \>=20 mm Hg change from baseline, DBP \<50 mm Hg; 2), PR \<40 or greater than (\>) 120 beats per minute (bpm). Baseline was defined as pre-treatment measurement on Day 1.

    Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)

  2. Number of Participants With Treatment-Emergent Adverse Events (All-Causality)

    Adverse event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device, regardless of its causal relationship with study treatment. An AE is considered treatment-emergent relative to a given treatment if: the event occurs for the first time during the effective duration of treatment and was not seen prior to the start of treatment (for example, during the baseline or run-in period); or the event was seen prior to the start of treatment but increased in severity during treatment.

    Time frame: Baseline (Visit 3) up to 31 days post last dose (75 days)

  3. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)

    ECG categorical summarization criteria: 1) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): absolute value greater than or equal to (\>=) 300 msec, percent change \>=25% if baseline was greater than (\>) 200 msec, and \>=50% if baseline was less than or equal to (\<=) 200 msec; 2) QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): absolute value \>=200 msec, percent change \>=25% if baseline was 100 msec, and \>=50% if baseline was \<=100 msec; 3) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value \>450 to \<=480 msec, \>480 to \<=500 msec, \>500 msec, an increase from baseline \>30 to \<=60 msec or \>60 msec. Baseline was defined as pre-treatment measurement on Day -2.

    Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)

  4. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Below parameters were evaluated:1), Hematology: hemoglobin (HGB), hematocrit, erythrocytes (absolute value/mean corpuscular volume/mean corpuscular HGB/mean corpuscular HGB concentration), platelets, leukocytes, lymphocytes, neutrophils, basophils, monocytes; 2), clinical chemistry: bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, amylase, triacylglycerol lipase; 3), urinalysis: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria.

    Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)

  5. Change From Baseline in Mean 48-hour Energy Intake at Visits 4 and 5

    Energy intake was measured over a period of 48 hours to assess day to day variability in food intake. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Baseline was defined as the 48 hour period at Visit 3 (Study Day -1 and 0).

    Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)

  6. Change From Baseline in Appetite Score (Mean Rating Area Under Curve From Time 30 to 120 Minutes [AUC30-120min]) for Mean Lunch at Visits 4 and 5

    Appetite, satiety, fullness, hunger, and prospective consumption were measured using a validated Visual Analog scale (VAS) questionnaire. VAS was an assessment in which participants place a vertical line across a validated 100 millimeter (mm) line with the example of "Not At All Full" and "Totally Full" at either end, scoring from 0 to 100. The overall appetite score was calculated as the average of the four individual scores \[satiety + fullness + (100 - prospective food consumption)+(100 - hunger)\] divided by 4. The VAS questionnaire was completed by the participant immediately prior to meal administration, and at 30, 60 and 120 minutes after start of the specified meals. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).

    Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)

  7. Change From Baseline in Satiety, Fullness, Prospective Food Consumption and Hunger Scores (Mean Rating AUC30-120min) for Mean Lunch at Visits 4 and 5

    Satiety, fullness, hunger, and prospective consumption were measured at the study site using a validated VAS questionnaire. The VAS measurement of the subcomponent scores were the same as that of the appetite score. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).The VAS was an assessment in which subjects place a vertical line across a validated 100 millimeter (mm) line to rank their response to various questions. The line was anchored by responses such as "Not At All Full" and "Totally Full" at either end. Scoring consisted of measuring the distance in mm of the vertical line from the response at the left end. The scores (total and subscale) ranged from 0 to 100. The lower values represent the better outcomes.The overall appetite score was calculated as the average of the 4 individual scores \[satiety+fullness+(100-prospective food consumption)+(100-hunger)\] divided by 4.

    Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)

  8. Change From Baseline in Area Under the Plasma Concentration-Time Profile of Acetaminophen for 0-60 Minutes and 0-300 Minutes (AUC0-60min and AUC0-300min) After Acetaminophen Dose at Visits 4 and 5

    A non investigational medicinal product (acetaminophen 1.5 gram \[g\]) was administered as a challenge agent for the assessment of gastric emptying. The blood sampling for determining acetaminophen concentrations was performed at 7 time points: prior to breakfast and at 30, 60, 90, 120, 180 and 300 minutes after intake of the acetaminophen with breakfast. Baseline was calculated at Visit 3 (Study Day -1).

    Time frame: Prior to breakfast and at 30,60,90,120,180 and 300 minutes after intake of the acetaminophen with breakfast on Visit 3,Visit 4 (Study Day 20) and Visit 5 (Study Day 41)

07

Results

Posted Jul 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneLiraglutidePlacebo
Started3229
Received treatment3228
Completed2826
Not completed43
Withdrew: Adverse event40
Withdrew: Death in the family02
Withdrew: Randomized but not treated01

Outcome measures

PrimaryChange From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5

The mean energy intake was collected to assess the effect of liraglutide on food intake in non-diabetic, obese participants. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Mean energy intakes at Visit 4 was defined as the mean values of the measurements at Study Day 20 and 21. Same definition applies to Visit 5 (Study Day 41 and 42). Baseline was defined as the mean of Visit 3 (Study Day -1 and 0).

Time frame:
Visit 3, Visit 4 and Visit 5
Reported as:
Mean · kilocalories (kcal)
Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5
kilocalories (kcal)LiraglutidePlacebo
Visit 4-254.48 ± 160.67-19.93 ± 162.12
Visit 5-278.78 ± 190.09-37.43 ± 164.49
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0000 (The p-value was calculated and was rounded to 4th decimal presenting as 0.0000, which was smaller than the required threshold of \<0.05.) · Least square mean difference: -235.75 · 95% CI -322.25 to -149.25
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0000 (The p-value was calculated and was rounded to 4th decimal presenting as 0.0000, which was smaller than the required threshold of \<0.05.) · Least square mean difference: -243.63 · 95% CI -339.10 to -148.15
SecondaryNumber of Participants With Vital Signs Data Meeting Categorical Criteria

Absolute values and changes from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR) were recorded in supine position. Vital signs categorical summarization criteria were 1), blood pressure: SBP greater than or equal to (\>=) 30 millimeters of mercury (mm Hg) change from baseline, SBP less than (\<) 90 mm Hg; DBP \>=20 mm Hg change from baseline, DBP \<50 mm Hg; 2), PR \<40 or greater than (\>) 120 beats per minute (bpm). Baseline was defined as pre-treatment measurement on Day 1.

Time frame:
Baseline (Visit 3) up to Visit 6 (Study Day 53)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Categorical Criteria
ParticipantsLiraglutidePlacebo
Supine DBP <50 mmHg35
Supine PR <40 bpm00
Supine PR >120 bpm00
Supine SBP <90 mmHg12
Increase in supine DBP >=20 mmHg31
Increase in supine SBP >=30 mmHg11
Decrease in supine DBP >=20 mmHg39
Decrease in supine SBP >=30 mmHg10
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (All-Causality)

Adverse event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device, regardless of its causal relationship with study treatment. An AE is considered treatment-emergent relative to a given treatment if: the event occurs for the first time during the effective duration of treatment and was not seen prior to the start of treatment (for example, during the baseline or run-in period); or the event was seen prior to the start of treatment but increased in severity during treatment.

Time frame:
Baseline (Visit 3) up to 31 days post last dose (75 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All-Causality)
ParticipantsLiraglutidePlacebo
Number of Participants With Treatment-Emergent Adverse Events (All-Causality)3120
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG)

ECG categorical summarization criteria: 1) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): absolute value greater than or equal to (\>=) 300 msec, percent change \>=25% if baseline was greater than (\>) 200 msec, and \>=50% if baseline was less than or equal to (\<=) 200 msec; 2) QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): absolute value \>=200 msec, percent change \>=25% if baseline was 100 msec, and \>=50% if baseline was \<=100 msec; 3) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value \>450 to \<=480 msec, \>480 to \<=500 msec, \>500 msec, an increase from baseline \>30 to \<=60 msec or \>60 msec. Baseline was defined as pre-treatment measurement on Day -2.

Time frame:
Baseline (Visit 3) up to Visit 6 (Study Day 53)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)
ParticipantsLiraglutidePlacebo
PR interval >=300 milliseconds (msec)00
QRS interval >=200 msec00
QTcF >450 - <=480 msec22
QTcF >480 - <=500 msec00
QTcF >500 msec00
PR interval percent increase >=25/50%00
QRS interval percent increase >=25/50%00
QTcF increase >30 - <=60 msec21
QTcF increase >60 msec00
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Below parameters were evaluated:1), Hematology: hemoglobin (HGB), hematocrit, erythrocytes (absolute value/mean corpuscular volume/mean corpuscular HGB/mean corpuscular HGB concentration), platelets, leukocytes, lymphocytes, neutrophils, basophils, monocytes; 2), clinical chemistry: bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, amylase, triacylglycerol lipase; 3), urinalysis: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria.

Time frame:
Baseline (Visit 3) up to Visit 6 (Study Day 53)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsLiraglutidePlacebo
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)3226
SecondaryChange From Baseline in Mean 48-hour Energy Intake at Visits 4 and 5

Energy intake was measured over a period of 48 hours to assess day to day variability in food intake. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Baseline was defined as the 48 hour period at Visit 3 (Study Day -1 and 0).

Time frame:
Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Reported as:
Mean · kcal
Change From Baseline in Mean 48-hour Energy Intake at Visits 4 and 5
kcalLiraglutidePlacebo
Visit 4-1058.8 ± 627.61-205.64 ± 608.51
Visit 5-1152.5 ± 745.71-242.84 ± 681.37
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0000 (The p-value was calculated and was rounded to 4th decimal presenting as 0.0000, which was smaller than the required threshold of \<0.05.) · Least square mean difference: -859.58 · 95% CI -1196.1 to -523.10
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0000 (The p-value was calculated and was rounded to 4th decimal presenting as 0.0000, which was smaller than the required threshold of \<0.05.) · Least square mean difference: -928.56 · 95% CI -1317.3 to -539.86
SecondaryChange From Baseline in Appetite Score (Mean Rating Area Under Curve From Time 30 to 120 Minutes [AUC30-120min]) for Mean Lunch at Visits 4 and 5

Appetite, satiety, fullness, hunger, and prospective consumption were measured using a validated Visual Analog scale (VAS) questionnaire. VAS was an assessment in which participants place a vertical line across a validated 100 millimeter (mm) line with the example of "Not At All Full" and "Totally Full" at either end, scoring from 0 to 100. The overall appetite score was calculated as the average of the four individual scores \[satiety + fullness + (100 - prospective food consumption)+(100 - hunger)\] divided by 4. The VAS questionnaire was completed by the participant immediately prior to meal administration, and at 30, 60 and 120 minutes after start of the specified meals. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).

Time frame:
Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Reported as:
Mean · units on a scale
Change From Baseline in Appetite Score (Mean Rating Area Under Curve From Time 30 to 120 Minutes [AUC30-120min]) for Mean Lunch at Visits 4 and 5
units on a scaleLiraglutidePlacebo
Visit 44.52 ± 8.65-0.60 ± 9.22
Visit 54.13 ± 9.99-0.99 ± 8.17
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0263 · Least square mean difference: 4.95 · 95% CI 0.61 to 9.29
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0121 · Least square mean difference: 5.35 · 95% CI 1.22 to 9.48
SecondaryChange From Baseline in Satiety, Fullness, Prospective Food Consumption and Hunger Scores (Mean Rating AUC30-120min) for Mean Lunch at Visits 4 and 5

Satiety, fullness, hunger, and prospective consumption were measured at the study site using a validated VAS questionnaire. The VAS measurement of the subcomponent scores were the same as that of the appetite score. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).The VAS was an assessment in which subjects place a vertical line across a validated 100 millimeter (mm) line to rank their response to various questions. The line was anchored by responses such as "Not At All Full" and "Totally Full" at either end. Scoring consisted of measuring the distance in mm of the vertical line from the response at the left end. The scores (total and subscale) ranged from 0 to 100. The lower values represent the better outcomes.The overall appetite score was calculated as the average of the 4 individual scores \[satiety+fullness+(100-prospective food consumption)+(100-hunger)\] divided by 4.

Time frame:
Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Reported as:
Mean · units on a scale
Change From Baseline in Satiety, Fullness, Prospective Food Consumption and Hunger Scores (Mean Rating AUC30-120min) for Mean Lunch at Visits 4 and 5
units on a scaleLiraglutidePlacebo
Satiety (Visit 4)3.94 ± 13.50-0.55 ± 10.52
Satiety (Visit 5)4.51 ± 11.791.02 ± 9.26
Fullness (Visit 4)4.04 ± 9.521.88 ± 10.85
Fullness (Visit 5)2.40 ± 10.081.89 ± 9.17
Prospective food consumption (Visit 4)-7.74 ± 12.871.59 ± 12.38
Prospective food consumption (Visit 5)-6.18 ± 16.924.23 ± 14.46
Hunger (Visit 4)-3.71 ± 7.972.13 ± 10.88
Hunger (Visit 5)-3.41 ± 8.962.63 ± 13.00
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.1768 · Least square mean difference: 3.98 · 95% CI -1.85 to 9.82
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.1137 · Least square mean difference: 3.43 · 95% CI -0.85 to 7.70
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.1858 · Least square mean difference: 2.85 · 95% CI -1.41 to 7.11
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.5288 · Least square mean difference: 1.41 · 95% CI -3.05 to 5.86
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0054 · Least square mean difference: -8.46 · 95% CI -14.30 to -2.61
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0117 · Least square mean difference: -9.78 · 95% CI -17.29 to -2.27
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0093 · Least square mean difference: -6.58 · 95% CI -11.48 to -1.69
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0296 · Least square mean difference: -6.39 · 95% CI -12.12 to -0.66
SecondaryChange From Baseline in Area Under the Plasma Concentration-Time Profile of Acetaminophen for 0-60 Minutes and 0-300 Minutes (AUC0-60min and AUC0-300min) After Acetaminophen Dose at Visits 4 and 5

A non investigational medicinal product (acetaminophen 1.5 gram \[g\]) was administered as a challenge agent for the assessment of gastric emptying. The blood sampling for determining acetaminophen concentrations was performed at 7 time points: prior to breakfast and at 30, 60, 90, 120, 180 and 300 minutes after intake of the acetaminophen with breakfast. Baseline was calculated at Visit 3 (Study Day -1).

Time frame:
Prior to breakfast and at 30,60,90,120,180 and 300 minutes after intake of the acetaminophen with breakfast on Visit 3,Visit 4 (Study Day 20) and Visit 5 (Study Day 41)
Reported as:
Mean · microgram*minute/milliliter (ug*min/mL)
Change From Baseline in Area Under the Plasma Concentration-Time Profile of Acetaminophen for 0-60 Minutes and 0-300 Minutes (AUC0-60min and AUC0-300min) After Acetaminophen Dose at Visits 4 and 5
microgram*minute/milliliter (ug*min/mL)LiraglutidePlacebo
AUC0-60min (Visit 4)18.30 ± 204.93-4.55 ± 262.11
AUC0-60min (Visit 5)81.19 ± 166.47-8.28 ± 258.55
AUC0-300min (Visit 4)197.79 ± 491.11-12.92 ± 489.50
AUC0-300min (Visit 5)394.22 ± 401.6247.31 ± 564.52
Statistical analysis
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.5008 · Least square mean difference: 35.56 · 95% CI -69.64 to 140.76
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0348 · Least square mean difference: 106.15 · 95% CI 7.86 to 204.44
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.1040 · Least square mean difference: 214.24 · 95% CI -45.59 to 474.07
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.0152 · Least square mean difference: 348.43 · 95% CI 70.20 to 626.66

Adverse events

Collected over From Baseline (Visit 3, Study Day -1 and Day 0) to Day 73.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide0/32 (0%)0/32 (0%)30/32 (93.8%)
Placebo0/28 (0%)0/28 (0%)18/28 (64.3%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventLiraglutidePlacebo
NauseaGastrointestinal disorders15/321/28
DiarrhoeaGastrointestinal disorders11/324/28
HeadacheNervous system disorders11/323/28
ConstipationGastrointestinal disorders9/323/28
Decreased appetiteMetabolism and nutrition disorders8/322/28
DyspepsiaGastrointestinal disorders7/322/28
Injection site bruisingGeneral disorders7/324/28
Abdominal pain upperGastrointestinal disorders6/321/28
VomitingGastrointestinal disorders6/320/28
DizzinessNervous system disorders6/321/28

Baseline characteristics

All participants who met the criteria stated below were included in the full analysis set (FAS): completed baseline assessment of food intake; received at least one dose of randomized, blinded investigational product (IP); and completed at least one post baseline measurement (after taking randomized IP).

Age, Continuous
Age, Continuous(years)LiraglutidePlaceboTotal
Mean43.0 ± 10.8848.1 ± 12.6345.4 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)LiraglutidePlaceboTotal
Female221638
Male81018
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LiraglutidePlaceboTotal
White211940
Black or African American9615
Asian011
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other000
Unknown000
08

Study locations

1 site
  • Translational Research Institute for Metabolism and Diabetes
    Orlando, Florida 32804, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2018, 10 months.

Results were first posted in Jul 2019, 1 year 6 months after primary completion.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2017
First posted
Feb 3, 2017
StartActual
Feb 20, 2017
Primary completionActual
Jan 16, 2018
CompletionActual
Jan 16, 2018
Results first posted
Jul 26, 2019
Last update
Jul 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03041792
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 3, 2017
Start date
Feb 20, 2017
Primary completion
Jan 16, 2018
Completion
Jan 16, 2018
Results posted
Jul 26, 2019
Last update
Jul 26, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion